Genmab A/S (NASDAQ:GMAB) Downgraded by Wall Street Zen to Hold

Genmab A/S (GMAB) Stock Analysis: Unveiling A 35.68% Upside Potential

Navigating the competitive waters of the biotechnology industry, Genmab A/S (NASDAQ: GMAB) continues to capture investor attention with its promising pipeline and solid financial metrics. Positioned in the healthcare sector, this Danish biotech firm boasts a market capitalization of $13.59 billion, underscoring its significant presence in the field of antibody-based cancer treatments. **Current Market Position and Valuation Insights** Genmab’s s…

Genmab A/S (NASDAQ:GMAB) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a buy rating to a hold rating in a report issued on Sunday morning. Several other equities analysts have also weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective (down from $50.00) on shares […]

Heico (NYSE:HEI) Rating Lowered to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Heico (NYSE:HEI – Free Report) from a buy rating to a hold rating in a research note published on Friday. HEI has been the subject of several other reports. Bank of America lifted their price objective on shares of Heico from $320.00 to $355.00 and gave the stock a […]

Sapiens International (NASDAQ:SPNS) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sapiens International (NASDAQ:SPNS – Free Report) from a buy rating to a hold rating in a research report released on Friday. Separately, Barclays lifted their target price on Sapiens International from $28.00 to $31.00 and gave the company an “underweight” rating in a research report on Friday, May 9th. […]